Glaucoma patients and suspects now have a new non-preserved treatment option thanks to the recent approval of Xelpros (latanoprost ophthalmic emulsion 0.005%). Manufacturer Sun Pharma says it’s the first and only latanoprost that does not contain benzalkonium chloride (BAK).
Chronic use of medications preserved with BAK can lead to ocular surface disruption, of particular concern in the predominantly elderly population of glaucoma patients, who are already at higher risk of tear film and ocular surface disorders. Xelpros is formulated with what the company calls ‘swollen micelle microemulsion’ technology that Sun says “helps to solubilize drugs that have limited or no solubility, thus eliminating the need for benzalkonium chloride.”
In randomized controlled clinical trials of patients with a mean baseline intraocular pressure (IOP) of 23mm Hg to 26mm Hg, treatment with Xelpros lowered IOP by a mean of up to 6mm Hg to 8mm Hg. The most frequently reported ocular adverse reactions were eye pain/stinging upon instillation and ocular hyperemia, reported in 55% and 41% of patients. Less than 1% of patients discontinued therapy because of intolerance to these adverse events.
Xelpros is approved for once-daily dosing. The product will be commercialized by Sun Ophthalmics, the branded ophthalmics division of Sun Pharma.